Wellington Management Group
LVTX

Wellington Management Group’s LAVA Therapeutics LVTX Stock Holding History

Wellington Management Group’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-203,800
Closed -$2.22M – 2219
2021
Q2 		$2.22M Buy
203,800
+58,400
+40% +$724K ﹤0.01% 1657
2021
Q1 		$2.21M Buy
+145,400
New +$2M ﹤0.01% 1606

Other funds holding LVTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.78B AUM 114.03% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group's LVTX Position: Q3 2021 in Review

Wellington Management Group sold out of LAVA Therapeutics (LVTX) in Q3 2021, closing a stake of 203,800 shares — an estimated $2.22M sold.

Wellington Management Group first reported a position in LVTX in Q1 2021 and held it in 2 quarters. The position peaked at $2.22M in Q2 2021. 19 funds tracked by Wall St. Rank hold LVTX as of Q3 2021.

  • Wellington Management Group reported no remaining LAVA Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Wellington Management Group sold 203,800 LAVA Therapeutics shares in Q3 2021, an estimated $2.22M.
  • Wellington Management Group first reported a position in LAVA Therapeutics in Q1 2021 and held it in 2 quarters.
  • Wellington Management Group's LAVA Therapeutics position peaked at $2.22M in Q2 2021.
  • 19 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q3 2021.

Based on Wellington Management Group's 13F filing for Q3 2021, filed 15 Nov 2021.